BioVenture appeared to be the VC, which was created in 2013. The main department of described VC is located in the Suzhou. The fund was located in Asia if to be more exact in China.
Speaking about the real fund results, this VC is 30 percentage points more often commits exit comparing to other organizations. Opposing the other organizations, this BioVenture works on 24 percentage points less the average amount of lead investments. Deals in the range of 10 - 50 millions dollars are the general things for fund. The increased amount of exits for fund were in 2018. The top activity for fund was in 2019. The fund is constantly included in 2-6 deals per year.
The fund has specific favorite in a number of founders of portfolio startups. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight inui Health, LAM Therapeutics, Innovita Biological Technology. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. Among the most successful fund investment fields, there are Health Diagnostics, Therapeutics.
The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the BioVenture, startups are often financed by Yueyin Venture Capital, Proxima Ventures Ltd, Luc De Vos. The meaningful sponsors for the fund in investment in the same round are OrbiMed, CD Capital, iGlobe Partners. In the next rounds fund is usually obtained by YuanMing Capital, Sanofi, Qiming Venture Partners.
This organization was formed by Jacky Chen.
Funds with similar focus
|$22M||09 Jun 2022||Shanghai, Shanghai, China|
|$7M||17 Feb 2022||Shenzhen, Guangdong, China|
|$15M||05 Jan 2022||Hangzhou, Zhejiang, China|
|$1M||28 Dec 2021||Tongzhou, Beijing, China|
|$47M||19 Nov 2021||China, Wuwei, China|
|$83M||10 Nov 2021||Dongcheng District, Beijing, China|
|$15M||08 Nov 2021||Shenzhen, Guangdong, China|
Tripod Preclinical Research Laboratories
|$154M||05 Nov 2021||Nanjing, Jiangsu, China|
|$40M||31 Oct 2021||Shangcheng District, Zhejiang, China|
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.